Registry for neuroimmunological diseases in China

National, Multicentric Registry Study on Neuroimmunological Diseases in China

This study is trying to gather information and samples from people with neuroimmunological diseases like Multiple Sclerosis and Myasthenia Gravis to learn more about their conditions and how they progress over time.

Quick facts

• Study type: Observational
• Enrollment: 7000 (estimated)
• Sex: All
• Sponsor: Xuanwu Hospital, Beijing (Academic / other)
• Locations: 1 site (Beijing, Beijing)
• Trial ID: NCT06443333 on ClinicalTrials.gov

What this trial studies

This study aims to establish a clinical cohort for neuroimmunological diseases, focusing on conditions such as Multiple Sclerosis and Myasthenia Gravis. It involves collecting biological samples like blood and cerebrospinal fluid from patients to identify new neural antibodies and understand the genetic factors involved in these diseases. Patients will be followed for two years to gather clinical data and assess disease progression. The study also includes healthy volunteers for comparative analysis.

Who should consider this trial

Good fit: Ideal candidates include patients diagnosed with Multiple Sclerosis, NMO Spectrum Disorder, Myasthenia Gravis, Autoimmune Encephalitis, or related conditions.

Not a fit: Patients without a diagnosis of the specified neuroimmunological diseases or those not treated at Xuanwu Hospital may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance the diagnosis and treatment of neuroimmunological diseases, leading to better patient outcomes.

How similar studies have performed: Other studies focusing on neuroimmunological diseases have shown promise in identifying biomarkers and improving treatment strategies, suggesting this approach has potential.

Eligibility criteria

Inclusion Criteria:

* Patients who diagnosed at Xuanwu Hospital, Capital Medical University with any of the following conditions:

  * Multiple Sclerosis (the criteria followed the Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria)
  * NMO Spectrum Disorder (the criteria followed the Diagnosis and Treatment Guidelines for Optic Neuromyelitis Spectrum Disorders in China 2016)
  * Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (the criteria followed the Consensus of Chinese Experts on Diagnosis and Treatment of Anti-Myelin Oligodendrocyte Glycoprotein Immunoglobulin G Antibody-Associated Diseases)
  * Myasthenia Gravis (the criteria followed the Guidelines for the Diagnosis and Treatment of Myasthenia Gravis in China 2020)
  * Autoimmune Encephalitis (the criteria followed the China Expert Consensus on Diagnosis and Treatment of Autoimmune Encephalitis 2017)
  * Acute Disseminated Encephalomyelitis (the criteria are based on the article titled "Acute disseminated encephalomyelitis" 2007).
* Healthy adults who underwent a physical examination at the Physical Examination Center of Xuanwu Hospital, Capital Medical University

Exclusion Criteria:

* Women during pregnancy or lactation.
* Patients with other neurological diseases or serious mental diseases.
* Patients with serious liver and kidney function or other important organ dysfunction.
* Unable to cooperate with follow-up work and venous blood collection due to poor compliance of patients or healthy volunteers, or incomplete clinical and imaging data.

Where this trial is running

Beijing, Beijing

• Xuanwu Hospital ,Capital Medical University — Beijing, Beijing, China (Recruiting)

Study contacts

• Principal investigator: Junwei Hao, MD — Xuanwu Hospital, Beijing
• Study coordinator: Junwei Hao, MD

Conditions Multiple Sclerosis; NMO Spectrum Disorder; Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease; Myasthenia Gravis; Autoimmune Encephalitis; Acute Disseminated Encephalomyelitis